Gregory A Carroll

US Patent:

20100331198, Dec 30, 2010

Filed:

Sep 11, 2007

Appl. No.:

11/900221

Inventors:

Denong Wang - Palo Alto CA, US
Gregory T. Carroll - New York NY, US
Nicholas J. Turro - Tenafly NJ, US
Jeffrey T. Koberstein - Storrs CT, US

International Classification:

C40B 30/04
C40B 40/12
C40B 50/18

US Classification:

506 9, 506 19, 506 32

Abstract:

The invention relates to novel photo-generated carbohydrate arrays and methods of their use to detect the presence of one or more agents in a sample. The invention also relates to a high-throughput strategy to facilitate the identification and immunological characterization of pathogen-specific carbohydrates, including those of . The invention can be used to determine the presence of a pathogen and whether a subject has been exposed to a pathogen, such as by screening for pathogen-specific antibodies.

US Patent:

20150265691, Sep 24, 2015

Filed:

Sep 14, 2007

Appl. No.:

11/901234

Inventors:

Denong Wang - Palo Alto CA, US
Pavol Kovac - Silver Spring MD, US
Lawrence Steinman - Stanford CA, US
Gregory Carroll - Cincinnati OH, US
Nicholas Turro - Tenafly NJ, US
Jeffrey Koberstein - Sturrs CT, US
Rina Saksena - Sturrs CT, US
Roberto Adamo - Siene, IT

International Classification:

A61K 39/07
G01N 33/68
G01N 33/569
A61K 47/48
C07K 16/12
C07K 16/42

Abstract:

This invention provides a vaccine comprising (i) an anthrose-containing saccharide in an amount effective to enhance immunity against in a subject and (ii) a pharmaceutically acceptable carrier. This invention provides a vaccine comprising (i) a conjugate of an anthrose-containing saccharide in an amount effective to enhance immunity against in a subject, wherein the anthrose-containing saccharide is conjugated to a biomolecule via a linker, and (ii) a pharmaceutically acceptable carrier. This invention provides a method for vaccinating a subject against infection comprising administering to the subject a vaccine comprising (i) an anthrose-containing saccharide in an amount effective to enhance immunity against in the subject and (ii) a pharmaceutically acceptable carrier, in an amount effective to stimulate production of antibodies to spores in the subject, thereby vaccinating the subject against